Pharmacomicrobiomics: a new field contributing to optimizing drug therapy in Parkinson’s disease
Gut microbiota, which act as a determinant of pharmacokinetics, have long been overlooked. In recent years, a growing body of evidence indicates that the gut microbiota influence drug metabolism and efficacy. Conversely, drugs also exert a substantial influence on the function and composition of the...
Saved in:
Main Authors: | Yi Zhang, Chengjun Mo, Penghui Ai, Xiaoqin He, Qin Xiao, Xiaodong Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2025-12-01
|
Series: | Gut Microbes |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/19490976.2025.2454937 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Improving breast cancer treatments using pharmacomicrobiomics
by: Aswin Anand Pai, et al.
Published: (2025-02-01) -
A review of gut microbiota as a therapeutic approach for Parkinson’s disease
by: Debosree Ghosh, et al.
Published: (2024-12-01) -
The Role of the Gastrointestinal Microbiota in Parkinson’s Disease
by: Maurizio Gabrielli, et al.
Published: (2024-12-01) -
The Microbiome-Gut-Brain Axis, Nutrition and Parkinson’s Disease
by: Jevgenija Guk, et al.
Published: (2024-03-01) -
Body and mind: how obesity triggers neuropsychiatric and neurodegenerative disorders
by: Claudio Pirozzi, et al.
Published: (2025-01-01)